ERAS: Erasca Inc Company Value to Net Income

Erasca Inc - graphic logo of issuer ERAS

Erasca, Inc. (ERAS) acts as a biotechnological pioneer, developing comprehensive RAS/MAPK pathway blocking schemes to combat tumor resistance. The company's strategy relies on diversifying its drug portfolio within clinical trials for various types of cancer. The price action history with the -16.90 metric clearly illustrates market expectations. Important data on melanoma therapy is expected ahead, while current R&D expenditures are not yet generating profit.

Price to Earnings Ratio: Erasca, Inc. (ERAS) for 07/04/2022 - 11/10/2026

Comprehensive metric breakdowns and analytics for Erasca Corp (ERAS)

- share price and expert price forecast:
Price Performance Chart erasca.com|ERAS - Consensus Target
- market capitalization information:
Market Value Erasca, Inc.|ERAS - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value per Share Erasca|ERAS - Company Net Assets|Market Capitalization to Book Value Ratio erasca.com|ERAS - Aggregate Company Assets
- debt and solvency information:
All Debt to Shareholders' Equity Ratio Erasca, Inc.|ERAS - Long-Term Debt to Capital|Current Liabilities to Capital Erasca Oncology|ERAS - Company Aggregate Debts|Debts to Book Value Erasca, Inc.|ERAS - Company Long-Term Debt|Company Short-Term Loans and Borrowings Erasca|Quick Ratio erasca.com
- company profitability and valuation multiples indicators:
ERAS - Company Net Income|Company Profit Forecast Erasca, Inc.|ERAS - P/E Multiple|Projected Price to Earnings Erasca Inc|ERAS - PEG Multiple|EV/EBITDA Multiple Erasca, Inc.|ERAS - Operating profit before deduction of amortization|Earnings per share for the trailing year Erasca|ERAS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months erasca.com|ERAS - Earnings per share growth in current year|Projected earnings per share growth rate for next year Erasca, Inc.
Summary company analysis:ERAS (erasca.com)
Flagship merchandise of Erasca

For Erasca, Inc. (ERAS), the P/E ratio serves as a tool for assessing market value relative to annual earnings. This metric is calculated as the ratio of market capitalization to net income, demonstrating the cost of one dollar of profit. By analyzing changes in the company's P/E ratio, an investor can observe the market's reaction to the risks associated with oncology drug clinical trials. The current liquidity reserve balances this volatility, ensuring financial stability until product commercialization.

Analysis of competing companies

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme)|RVMD (Revolution Medicines Inc) - Company Value to Net Income|P/E Multiple AAPG (Ascentage)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis (PSNL) - Price to Earnings Ratio|Delcath Systems Inc - Company Value to Net Income|YMAB (YmAbs) - P/E Multiple|Market Cap to Earnings Aura Corp AURA|P/E Multiple CADL|ARAY - Market Cap to Earnings|Price to Earnings Ratio SELLAS Life Sciences Group SLS|Company Value to Net Income ACTU|Citius Oncology, Inc - P/E Multiple|HURA - P/E Multiple|Protara Therapeutics (TARA) - Price to Earnings Ratio|FATE - Business Payback Period|WHWK (Aadi Bioscience, Inc.) - P/E Multiple|Price to Earnings Ratio TScan (TCRX)|P/E Multiple CSBR|P/E Multiple xbiotech.com (XBIT)|CEL-SCI - Price to Earnings Ratio|Company Value to Net Income OSTX|Radiopharm Theranostics - P/E Multiple|Business Payback Period Artiva Biotherapeutics, Inc. ARTV|adlainortye.com (ANL) - Price to Earnings Ratio|Price to Earnings Multiple VERU|TPST (Tempest Therapeutics) - P/E Multiple|Price to Earnings Ratio Xilio (XLO)|Price to Earnings Ratio RENB (Renovaro Inc.)|Business Payback Period muraloncology.com|P/E Multiple KAPA (Kairos Pharma)|OnKure Therapeutics, Inc. (OKUR) - Market Cap to Earnings|GDTC - Price to Earnings Ratio|Company Value to Net Income CRIS (Curis, Inc.)|APLM: P/E Multiple|Tharimmune Inc (THAR) - P/E Multiple|Price to Earnings Ratio Advanced Biomed Inc.|Genprex Inc (GNPX) - Business Payback Period|P/E Multiple CLDI|Price to Earnings Ratio sunshinebiopharma.com SBFM|P/E Multiple XBIO (Xenetic Biosciences, Inc.)|P/E Multiple Salarius Pharmaceuticals Inc SLRX|PPBT - Price to Earnings Ratio|AONC (American Oncology Network) - Price to Earnings Multiple|BGNE: P/E Multiple|Price to Earnings Ratio checkpointtx.com|ELEV (Elevation Oncology) - P/E Multiple|Market Cap to Earnings iCAD Corp ICAD|Price to Earnings Ratio Ikena Oncology, Inc. (IKNA)|NTBL (Notable Labs Corp) - Company Value to Net Income|Viracta Therapeutics, Inc. - Price to Earnings Ratio|Company Value to Net Income MOR|NAYA Biosciences Inc. - P/E Multiple|Ascentage Pharma Group International (AAPGV) - Price to Earnings Ratio